Spots Global Cancer Trial Database for refractory childhood acute lymphoblastic leukemia

Every month we try and update this database with for refractory childhood acute lymphoblastic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Ex Vivo Drug Sensitivity Testing and Mutation Profiling	NCT03860376	Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chil... Refractory Chil... Refractory Chil... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro...		1 Day - 21 Years	Florida International University
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT02819804	B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil...	Dasatinib Laboratory Biom... Nivolumab Pharmacological...	18 Years -	Northwestern University
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	NCT01858740	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil...	Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra...	- 21 Years	Fred Hutchinson Cancer Center
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT02819804	B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil...	Dasatinib Laboratory Biom... Nivolumab Pharmacological...	18 Years -	Northwestern University
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT02819804	B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil...	Dasatinib Laboratory Biom... Nivolumab Pharmacological...	18 Years -	Northwestern University
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	NCT01858740	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil...	Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra...	- 21 Years	Fred Hutchinson Cancer Center
Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia	NCT02819804	B Acute Lymphob... Recurrent Adult... Recurrent Child... Refractory Adul... Refractory Chil...	Dasatinib Laboratory Biom... Nivolumab Pharmacological...	18 Years -	Northwestern University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: